<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>34605</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1471-2288-1-6</infon><infon key="article-id_pmc">34605</infon><infon key="article-id_pmid">11459516</infon><infon key="article-id_publisher-id">1471-2288-1-6</infon><infon key="fpage">6</infon><infon key="journal-title">BMC Medical Research Methodology</infon><infon key="lpage">6</infon><infon key="name_0">surname:Vickers;given-names:Andrew J</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">1</infon><infon key="year">2001</infon><offset>0</offset><text>The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>128</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>139</offset><text>The statistical power of each method for testing a hypothetical randomized trial with varying correlations between baseline and post-treatment scores was determined by comparing four different methods.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>711</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>719</offset><text>When it comes to statistical power, ANCOVA is the most robust, while post-treatment and baseline correlations are more reliable. However, it is still reasonable to only consider changes made after treatment treatment adjustments, as these tend to be sensitive to fluctuations in variance. Furthermore, there are some theoretical considerations that suggest percentage change from baseline is not a good measure of baseline safety and will result in excessive trials with non-normally distributed outcome data.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1292</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1304</offset><text>The use of percentage change from baseline is not recommended in statistical analysis. Those who want to report this statistic should use a different technique, such as ANCOVA, and convert the results to corresponding percentage changes by using mean baseline scores.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1544</offset><text>The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study

Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1555</offset><text>A randomized trial is often used to assess the continuous outcome at both the beginning and end of treatment, as demonstrated by studies on pravastatin for hypercholesterolemia, exercise and diet for obesity patients, and acupuncture for pain in athletes with shoulder injuries.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2045</offset><text>In statistical analysis of trials that evaluate outcomes, there are four methods for including data in the analysis: using the baseline score alone and entering only the post-treatment score (as described in "POST"); analyzing the change from baseline either through absolute differences ("CHANGE") or through a percentage change to baseline ("FRACTION") via constructing &#8212; by means of least common mathematical approach&#8212;a regression model that adjusts the outcome of the treatment by the base score. Figure 1 shows how each method could be used to analyze the outcomes of these treatments with the same as an example showing how many people who had been treated</text></passage><passage><infon key="file">1471-2288-1-6-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>2827</offset><text>Mathematical description of the four methods</text></passage><passage><infon key="file">1471-2288-1-6-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>2872</offset><text>Examples of the results of a trial analyzed by each method in ordinary language terms</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2958</offset><text>In some trials, the outcome can be measured several times after treatment using a design known as "repeated measures". These trials can then be analysed using an area-under-curve or summary statistic such as momentum" or lma (repetitive measures analysis of variance) and more complex linear estimation methods. These methods are particularly useful when post-treatment scores show cyclic events (e.g. quality of life in late stage cancer patients) or when it is important to assess how treatment affects effects.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3721</offset><text>By examining the statistical characteristics of each method, one can determine which one to use. An important factor to consider is that a good statistical method should have fewer false negatives () and be low enough to reduce the rate of errors. The statistical power (1-1) is used to measure statistical tests, with power usually being set at either 0.8 or 0.89, and data must be obtained in quantities such as the required number of evaluable patients. Economists describe an efficient method that requires less data to provide varying levels of data.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4282</offset><text>The four methods POST, CHANGE, FACTION and ANCOVA have been the subject of research by statisticians for some time. In this paper, I will compare them using a hypothetical trial and demonstrate their statistical power with examples that are useful in clinical research.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4662</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4670</offset><text>All calculations and simulations were conducted using the statistical software Stata 6.0 (Stata Corp., College Station, Texas). I created a hypothetical pain trial with patients divided evenly between a treatment and a control group. The pain score for any individual patient was sampled from a normal distribution. The mean score at baseline was 50 mm on a visual analog scale of pain (VAS); after treatment, mean pain was expected to be 50 mm in controls and 45 mm in treated patients. The standard deviation of all scores was 10. The text of the simulation is given in the appendix (appendix.doc).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5271</offset><text>I calculated the statistical power of the different methods of analysis for this trial given a sample size of 100 patients. As power varies according to the correlation between baseline and follow-up scores, a range of different possible correlations were used. The power for POST, CHANGE and ANCOVA were calculated using the "sampsi" function of Stata. This derives power analytically using formula developed by Frison and Pocock. The power for FRACTION was calculated by the simulation described above. The simulation was first validated against Stata's results for POST and CHANGE at a correlation of 0.5. It was then conducted using 1000 repetitions calculating ttests for FRACTION at a range of correlations between 0.2 and 0.8. The number of results in which p was less than 5% was calculated.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>6071</offset><text>Results and Discussion</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6094</offset><text>The true positive rates of the four statistical methods given different correlations are given in table 1. These data are equivalent to statistical power, or 1-&#946;. As has been previously reported, ANCOVA has the highest statistical power. CHANGE has acceptable power when correlation between baseline and post-treatment scores are high;when correlations are low, POST has reasonable power. FRACTION has poor statistical efficiency at all correlations.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>6548</offset><text>Statistical power of each method of analysis</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;Correlation&lt;/td&gt;&lt;td align="center"&gt;&#961; = 0.2&lt;/td&gt;&lt;td align="center"&gt;&#961; = 0.35&lt;/td&gt;&lt;td align="center"&gt;&#961; = 0.5&lt;/td&gt;&lt;td align="center"&gt;&#961; = 0.65&lt;/td&gt;&lt;td align="center"&gt;&#961; = 0.8&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;POST&lt;/td&gt;&lt;td align="center"&gt;70.5%&lt;/td&gt;&lt;td align="center"&gt;70.5%&lt;/td&gt;&lt;td align="center"&gt;70.5%&lt;/td&gt;&lt;td align="center"&gt;70.5%&lt;/td&gt;&lt;td align="center"&gt;70.5%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;FRACTION&lt;/td&gt;&lt;td align="center"&gt;45.1%&lt;/td&gt;&lt;td align="center"&gt;56.4%&lt;/td&gt;&lt;td align="center"&gt;67.0%&lt;/td&gt;&lt;td align="center"&gt;82.7%&lt;/td&gt;&lt;td align="center"&gt;97.1%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;CHANGE&lt;/td&gt;&lt;td align="center"&gt;50.7%&lt;/td&gt;&lt;td align="center"&gt;59.2%&lt;/td&gt;&lt;td align="center"&gt;70.5%&lt;/td&gt;&lt;td align="center"&gt;84.8%&lt;/td&gt;&lt;td align="center"&gt;97.7%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;ANCOVA&lt;/td&gt;&lt;td align="center"&gt;72.3%&lt;/td&gt;&lt;td align="center"&gt;76.1%&lt;/td&gt;&lt;td align="center"&gt;82.3%&lt;/td&gt;&lt;td align="center"&gt;90.8%&lt;/td&gt;&lt;td align="center"&gt;98.6%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>6593</offset><text>Correlation	&#961; = 0.2	&#961; = 0.35	&#961; = 0.5	&#961; = 0.65	&#961; = 0.8	 	POST	70.5%	70.5%	70.5%	70.5%	70.5%	 	FRACTION	45.1%	56.4%	67.0%	82.7%	97.1%	 	CHANGE	50.7%	59.2%	70.5%	84.8%	97.7%	 	ANCOVA	72.3%	76.1%	82.3%	90.8%	98.6%	 	</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6816</offset><text>Moreover, the power of FRACTION is sensitive to changes in the characteristics of the baseline distribution. If the range of baseline values is large, the variance of FRACTION increases disproportionately and power falls. Simulations were repeated with the standard deviations and difference between groups doubled. There was no difference in the power of POST, CHANGE or ANCOVA. The power of FRACTION fell dramatically: at correlations of 0.2, 0.35, 0.5, 0.65 and 0.8 respectively, power was 18%, 24%, 33%, 45% and 63%.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7337</offset><text>It is arguable that the method of simulation is biased against FRACTION because the treatment effect is additive, that is, the simulation models an absolute 5 mm difference between groups. In theory, the difference between FRACTION and CHANGE should decrease if the treatment effect is proportional. The simulation was therefore repeated with the treatment group experiencing an average 10% decrease from baseline. Correlation between baseline and follow-up scores was varied randomly between 0.2 and 0.8. The p values from a ttest of FRACTION and CHANGE were directly compared over 1000 simulations: p values were lower for CHANGE approximately 65% of the time.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8000</offset><text>Theoretical considerations suggestion two further disadvantages to FRACTION. First, because it incorporates both baseline and post-treatment scores, it would appear to control for any chance baseline imbalance between groups. However, this is not the case because of regression to the mean: FRACTION will create a bias towards the group with poorer baseline scores (the same is true for CHANGE; POST causes bias in the opposite direction). Second, because it is calculated using a ratio, it may cause outcome data to be non-normally distributed. In a bivariate normal distribution (such as a baseline and post-treatment score) any statistic using either variable alone or combining both by addition or subtraction will be normally distributed. There is no analytic reason why a statistic created by multiplying or dividing one variable by the other should necessarily have a normal distribution.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>8896</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>8907</offset><text>The percentage change in outcome from baseline during a randomized trial provides clinically relevant information to both patients and clinicians, which is likely why researchers studying hot flashes or the effects of different chemotherapy regimens on quality of life report this statistic.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>9263</offset><text>Using percentage change from baseline is not an efficient method for reporting statistical data, as it does not correct for imbalance between groups at baseline and can result in a non-normally distributed statistic. Trialists should use another technique, such as ANCOVA, to test significance and calculate confidence intervals. They should then convert their results into percentage difference by using both baseline (8000) and post-treatment scores.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>9909</offset><text>Results here restate earlier data that suggests previously reported data indicating that ANCOVA is the preferred method for analyzing results of trials in which baseline and post treatment measurements were taken, although other methods such as CHANGE or POST could be used instead, given that the assumptions under ANNOVC modeling do not appear to work (for instance, with small samples) and those where the correlation between baseline variables may be maintained through stratification; therefore there will always have been some level of agreement among groups for both outcomes, so either FRACTION or low.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>10520</offset><text>Competing interests</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>10540</offset><text>Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this paper?</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>10724</offset><text>No</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>10727</offset><text>Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper?</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>10860</offset><text>No</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>10863</offset><text>Do you have any other financial competing interests?</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>10916</offset><text>No</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>10919</offset><text>Are there any non-financial competing interests you would like to declare in relation to this paper?</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>11020</offset><text>No</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>11023</offset><text>Pre-publication history</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>11047</offset><text>The pre-publication history for this paper can be accessed here:</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>11112</offset><text>Supplementary Material</text></passage><passage><infon key="fpage">1281</infon><infon key="lpage">1286</infon><infon key="name_0">surname:Glorioso;given-names:N</infon><infon key="name_1">surname:Troffa;given-names:C</infon><infon key="name_2">surname:Filigheddu;given-names:F</infon><infon key="name_3">surname:Dettori;given-names:F</infon><infon key="name_4">surname:Soro;given-names:A</infon><infon key="name_5">surname:Parpaglia;given-names:PP</infon><infon key="name_6">surname:Collatina;given-names:S</infon><infon key="name_7">surname:Pahor;given-names:M</infon><infon key="pub-id_pmid">10601131</infon><infon key="section_type">REF</infon><infon key="source">Hypertension</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">1999</infon><offset>11135</offset><text>Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.</text></passage><passage><infon key="fpage">1062</infon><infon key="lpage">1072</infon><infon key="name_0">surname:Messier;given-names:SP</infon><infon key="name_1">surname:Loeser;given-names:RF</infon><infon key="name_2">surname:Mitchell;given-names:MN</infon><infon key="name_3">surname:Valle;given-names:G</infon><infon key="name_4">surname:Morgan;given-names:TP</infon><infon key="name_5">surname:Rejeski;given-names:WJ</infon><infon key="name_6">surname:Ettinger;given-names:WH</infon><infon key="pub-id_pmid">10983905</infon><infon key="section_type">REF</infon><infon key="source">J Am Geriatr Soc</infon><infon key="type">ref</infon><infon key="volume"> 48</infon><infon key="year">2000</infon><offset>11270</offset><text>Exercise and weight loss in obese older adults with knee osteoarthritis: a preliminary study.</text></passage><passage><infon key="fpage">235</infon><infon key="lpage">241</infon><infon key="name_0">surname:Kleinhenz;given-names:J</infon><infon key="name_1">surname:Streitberger;given-names:K</infon><infon key="name_2">surname:Windeler;given-names:J</infon><infon key="name_3">surname:Gussbacher;given-names:A</infon><infon key="name_4">surname:Mavridis;given-names:G</infon><infon key="name_5">surname:Martin;given-names:E</infon><infon key="pub-id_doi">10.1016/S0304-3959(99)00107-4</infon><infon key="pub-id_pmid">10534595</infon><infon key="section_type">REF</infon><infon key="source">Pain</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">1999</infon><offset>11364</offset><text>Randomised clinical trial comparing the effects of acupuncture and a newly designed placebo needle in rotator cuff tendinitis.</text></passage><passage><infon key="fpage">230</infon><infon key="lpage">235</infon><infon key="name_0">surname:Matthews;given-names:JNS</infon><infon key="name_1">surname:Altman;given-names:D</infon><infon key="name_2">surname:Campbell;given-names:MJ</infon><infon key="name_3">surname:Royston;given-names:P</infon><infon key="pub-id_pmid">2106931</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">300</infon><infon key="year">1990</infon><offset>11491</offset><text>Analysis of serial measurements in medical research.</text></passage><passage><infon key="fpage">1587</infon><infon key="lpage">1603</infon><infon key="name_0">surname:Omar;given-names:RZ</infon><infon key="name_1">surname:Wright;given-names:EM</infon><infon key="name_2">surname:Turner;given-names:RM</infon><infon key="name_3">surname:Thompson;given-names:SG</infon><infon key="pub-id_doi">10.1002/(SICI)1097-0258(19990715)18:13&lt;1587::AID-SIM141&gt;3.0.CO;2-Z</infon><infon key="pub-id_pmid">10407231</infon><infon key="section_type">REF</infon><infon key="source">Stat Med</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1999</infon><offset>11544</offset><text>Analysing repeated measurements data: a practical comparison of methods.</text></passage><passage><infon key="name_0">surname:Harris;given-names:CW;suffix:Ed</infon><infon key="section_type">REF</infon><infon key="source">Madison: University of Wisconsin Press</infon><infon key="type">ref</infon><infon key="year">1967</infon><offset>11617</offset><text>Problems in measuring change.</text></passage><passage><infon key="fpage">1685</infon><infon key="lpage">1704</infon><infon key="name_0">surname:Frison;given-names:L</infon><infon key="name_1">surname:Pocock;given-names:SJ</infon><infon key="pub-id_pmid">1485053</infon><infon key="section_type">REF</infon><infon key="source">Stat Med</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1992</infon><offset>11647</offset><text>Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design.</text></passage><passage><infon key="name_0">surname:S;given-names:Senn</infon><infon key="section_type">REF</infon><infon key="source">Chichester: John Wiley</infon><infon key="type">ref</infon><infon key="year">1997</infon><offset>11757</offset><text>Statistical Issues in Drug Development.</text></passage><passage><infon key="fpage">347</infon><infon key="lpage">352</infon><infon key="name_0">surname:Loprinzi;given-names:CL</infon><infon key="name_1">surname:Michalak;given-names:JC</infon><infon key="name_2">surname:Quella;given-names:SK</infon><infon key="name_3">surname:O'Fallon;given-names:JR</infon><infon key="name_4">surname:Hatfield;given-names:AK</infon><infon key="name_5">surname:Nelimark;given-names:RA</infon><infon key="name_6">surname:Dose;given-names:AM</infon><infon key="name_7">surname:Fischer;given-names:T</infon><infon key="name_8">surname:Johnson;given-names:C</infon><infon key="name_9">surname:Klatt;given-names:NE</infon><infon key="pub-id_doi">10.1056/NEJM199408113310602</infon><infon key="pub-id_pmid">8028614</infon><infon key="section_type">REF</infon><infon key="source">N Engi J Med</infon><infon key="type">ref</infon><infon key="volume">331</infon><infon key="year">1994</infon><offset>11797</offset><text>Megestrol acetate for the prevention of hot flashes.</text></passage><passage><infon key="fpage">447</infon><infon key="lpage">453</infon><infon key="name_0">surname:Anderson;given-names:H</infon><infon key="name_1">surname:Hopwood;given-names:P</infon><infon key="name_10">surname:Burt;given-names:PA</infon><infon key="name_11">surname:Connolly;given-names:CK</infon><infon key="name_12">surname:Mclllmurray;given-names:MB</infon><infon key="name_13">surname:Carmichael;given-names:J</infon><infon key="name_2">surname:Stephens;given-names:RJ</infon><infon key="name_3">surname:Thatcher;given-names:N</infon><infon key="name_4">surname:Cottier;given-names:B</infon><infon key="name_5">surname:Nicholson;given-names:M</infon><infon key="name_6">surname:Milroy;given-names:R</infon><infon key="name_7">surname:Maughan;given-names:TS</infon><infon key="name_8">surname:Falk;given-names:SJ</infon><infon key="name_9">surname:Bond;given-names:MG</infon><infon key="pub-id_doi">10.1054/bjoc.2000.1307</infon><infon key="pub-id_pmid">10945489</infon><infon key="section_type">REF</infon><infon key="source">Br J Cancer</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">2000</infon><offset>11850</offset><text>Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.</text></passage><passage><infon key="fpage">A2070</infon><infon key="lpage">2076</infon><infon key="name_0">surname:Crouse;given-names:JR;suffix:3rd</infon><infon key="name_1">surname:Morgan;given-names:T</infon><infon key="name_2">surname:Terry;given-names:JG</infon><infon key="name_3">surname:Ellis;given-names:J</infon><infon key="name_4">surname:Vitolins;given-names:M</infon><infon key="name_5">surname:Burke;given-names:GL</infon><infon key="pub-id_doi">10.1001/archinte.159.17.2070</infon><infon key="pub-id_pmid">10510993</infon><infon key="section_type">REF</infon><infon key="source">Arch Intern Med</infon><infon key="type">ref</infon><infon key="volume">159</infon><infon key="year">1999</infon><offset>12064</offset><text>A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins.</text></passage></document></collection>